AAPM 2021

2021

AAPM 2021 will take place February 3-7, 2021 in Phoenix, AZ.

 Join the AAPM 2021 mail list to receive the latest news and information about the meeting, including when the call for session proposals and scientific poster abstracts become available.

 SIGN UP

 

Read more...

Katherine Martucci, PhD -- Duke University

Katherine Martucci, PhD, is a neuroscientist who specializes in human clinical research of chronic pain, reward and motivation behaviors, sensory and acute pain perception, and opioid use and addiction. Dr. Martucci serves as Director of the Human Affect and Pain Neuroscience Lab which uses a combination of neuroimaging techniques, including functional magnetic resonance imaging (fMRI) of the brain and cervical spinal cord, as well as sensory, behavioral and psychological tests to study acute and chronic pain in humans.

As part of the Center for Translational Pain Medicine (CTPM) at Duke, Dr. Martucci’s lab is in the Department of Anesthesiology and conducts research in collaboration with the Brain Imaging and Analysis Center (BIAC) and Duke Institute for Brain Sciences (DIBS). Dr. Martucci earned her PhD in Neurobiology and Anatomy at Wake Forest School of Medicine and continued her training in clinical research with a postdoctoral fellowship at Stanford University.

Read more...

AJOVY® (fremanezumab-vfrm) Injection: An anti-CGRP for the Preventive Treatment of Migraine in Adults

Faculty

Charles E. Argoff , MD, CPE
Professor of Neurology
Albany Medical College
Director, Comprehensive Pain Center
Albany Medical Center
Albany, NY

Educational Objectives

After attending this symposium, participants should be better able to:

  • Provide a review of migraine impact, diagnosis, and treatment guidelines
  • Review recent information on migraine pathophysiology and the role of CGRP in ­migraine
  • Discuss clinical trial study design and background on AJOVY as an anti-CGRP for the preventive treatment of migraine in adults
  • Review the efficacy, safety, and dosing/ administration of AJOVY in clinical trials

Description

During this presentation, faculty will provide an overview of AJOVY® (fremanezumab-vfrm) injection as a preventive treatment of migraine in adults. The presentation will begin with a discussion of the migraine disease state, including migraine pathophysiology. This will be followed by a review of the efficacy and safety of AJOVY. Additionally, participants will have the opportunity to ask questions of the faculty.

IMPORTANT SAFETY_INFORMATION (continued)

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.

Adverse Reactions: The most common adverse reactions (_5% and greater than placebo) were injection site reactions.

Activity sponsored by: Teva Pharmaceuticals

Emerging Trends in Migraine Diagnosis and Treatment

Educational Objectives

After attending this symposium, participants should be better able to:

  • Explore the underlying biology that establishes migraine as a neurological disease
  • Understand the impact of migraine on patients’ daily lives
  • Understand how to diagnose and classify migraine

Description

This presentation will discuss migraine diagnosis, classification and treatment as well as migraine-associated patient burden.

Activity sponsored by: Novartis

A Common Sense Approach to: Lawsuit Prevention, Tax Reduction & License Protection

Faculty

Art McOmber
Barb McOmber
Natalia McOmber
Daniel McOmbie

Educational Objectives

After attending this symposium, participants should be better able to:

  • Keep their name and license off of the NPDB.
  • Eliminate costly legal fees associated with lawsuits.
  • Protect their earning power.
  • Utilize proven tax strategies.

Description

Legally Mine is an asset protection and tax strategy group. The mission of Legally Mine is to empower members of the healthcare community with the knowledge and tools to protect their assets from lawsuits, build professional license safeguards into their legal structures and legitimately reduce their tax liability.

Activity Sponsored by: Legally Mine

Opioid Induced Respiratory Depression – latest thinking – is safety within our reach?

Faculty 

Dr Martin Cheatle PhD. Director, Behavioral Medicine - Penn Pain Medicine Center. Associate Professor of Psychology in Psychiatry at the Hospital of the University of Pennsylvania
Dr Andrew Germanovich DO. Anesthesiologist, Orange County, Ca.

Educational Objectives

After attending this symposium, participants should be better able to:

  • Understand latest understanding of, and risks from, OIRD.
  • Understand who is at risk and how Physicians can minimize the issue.
  • Learn of latest thinking around how to prevent OIRD in the future.

Description

Over 100 Americans die every day due to OIRD, yet it is not well understood by patients and some Physicians. This Symposium will take participants through the latest thinking and science, and define who is at risk in each segment of the population, from those with legitimate prescriptions, to those misusing Opioids. It will cover issues of concomitant medications and how they impact the risk profile, and will guide participants through the best ways to mitigate risk in a highly vulnerable population.

Activity sponsored by: Masimo

Women in Pain Medicine SIG Reception

All AAPM 2020 meeting participants –women and men! – with an interest in recruiting and nurturing the careers of women in pain medicine are encouraged to attend the Women in Pain Medicine SIG Reception. SIG Chairs, Susan Moeschler, MD, and Stephanie Neuman, MD, will lead an evening of conversation and engagement.

Dr. Tina Doshi will deliver a timely presentation about diversity in pain medicine.